The Pro Medicus Ltd (ASX: PME) share price is in focus today after the company signed a new five-year, $23 million contract with the University of Maryland Medical System, with its Visage 7 cloud platform to be rolled out across the network.
What did Pro Medicus report?
- Signed a five-year, $23 million contract with the University of Maryland Medical System (UMMS)
- Contract covers Visage 7 Viewer and Visage 7 Workflow solutions
- Full implementation to be delivered through a cloud-based platform
- Contract uses a transaction-based licensing model, with potential for increased revenue
What else do investors need to know?
The UMMS partnership extends Pro Medicus’ reach across multiple prominent health sites in Maryland, including major hospitals and trauma centres. This adds to a growing client list for the company’s cloud-based imaging solutions, especially in the North American market.
Implementation of the Visage 7 platform will start immediately, with the target for completion and go-live set for early 2027. The transaction-based model could offer upside for Pro Medicus if usage volumes increase over the contract term.
What’s next for Pro Medicus?
With the UMMS rollout planned for early 2027, Pro Medicus will deliver and implement its Visage 7 imaging platform across an extensive network, supporting radiologist efficiency and specialist workflows. Management has highlighted a strong pipeline spanning all market segments.
As cloud-based imaging becomes more widely adopted in healthcare, Pro Medicus aims to remain a leader in providing scalable and efficient solutions for clients in Australia, North America, and beyond.
Pro Medicus share price snapshot
Over the past 12 months, Pro Medicus shares have declined 35%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 16% over the same period.
The post Pro Medicus announces $23m US contract appeared first on The Motley Fool Australia.
Should you invest $1,000 in Pro Medicus right now?
Before you buy Pro Medicus shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Pro Medicus wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- DroneShield posts record revenue and unveils leadership changes
- Magellan Financial Group posts March 2026 AUM drop
- Regis Resources posts strong Q3 cash build and gold production
- Flight Centre Travel Group sells Pedal Group stake for $61.7 million
- Greatland Resources posts March quarter update
Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.